Catalog No.
Product Name
Application
Product Information
Citations
-
MAO Inhibitor
Moclobemide is a reversible and selective inhibitor of monoamine oxidase A (MAO-A).- Linyu Cao, .et al. , Eur J Pharmacol, 2020, Jun 5;876:173058 PMID: 32131022
-
MAO-B inhibitor
Quercetin inhibits many enzyme systems including tyrosine protein kinase, phospholipase A2, phosphodiesterases, mitochondrial ATPase, PI 3-kinase and protein kinase C.- Sumayyah Saeed, .et al. , Int J Mol Sci, 2025, Jan 14;26(2):654 PMID: 39859369
-
Monoamine oxidase inhibitor
Rasagiline is an irreversible inhibitor of monoamine oxidase used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. It is selective for MAO type B over type A by a factor of fourteen. -
MAO-A inhibitor
Salsolidine is a tetrahydroisoquinoline alkaloid, acts as a stereoselective competitive MAO A inhibitor. -
MAO-B inhibitor
Safinamide is a highly selective and reversible monoamine oxidase type B (MAO-B) inhibitor that increases neostriatal dopamine concentration. -
alpha-adrenergic receptor agonist / MAO inhibitor
Amitraz, also known as Mitaban and Taktic, is an alpha-adrenergic receptor agonist and MAO inhibitor used as an insecticide in prevention of flea and tick infections. It prevents prostaglandin synthesis and may inhibit beta-cell insulin release. -
MAO inhibitor
Pargyline hydrochloride is an irreversible inhibitor of monoamine oxidase (MAO) that is used clinically to treat moderate hypertension. -
monoamine oxidase A inhibitor
Clorgyline hydrochloride is an irreversible and selective inhibitor of monoamine oxidase A (MAO-A) that is used in scientific research; structurally related to Pargyline. - Harmaline is a psychoactive indole found naturally in certain plants. Its stimulating activities are achieved, in part, through inhibition of monoamine oxidases, thus increasing the levels of monoamine neurotransmitters (e.g., at 7-70 μM/kg in rats). Harmaline (30 mg/kg) induces tremor in mice through the N-methyl-D-aspartate (NMDA) receptor, at which harmaline may act as an inverse agonist.
-
MAO inhibitor
Iproniazid is a non-selective, irreversible monoamine oxidase (MAO) inhibitor (MAOI) that is used as an antidepressive agent. -
MAO inhibitor
Molindone HCl is a D2 dopamine receptor antagonist. It also acts as a MAO inhibitor. -
monoamine oxidase inhibitor
Isocarboxazid is a non-selective and irreversible inhibitor of monoamine oxidase, with an IC50 of 4.8 μM for rat brain monoamine oxidase in vitro. -
MAO-A inhibitor
Toloxatone (MD 69276) is a reversible monoamine oxidase A (MAOA) inhibitor. Antidepressant. -
MAO inhibitor
Iproniazid phosphate is an irreversible inhibitor of monoamine oxidase types A and B that is used as an antidepressive agent. It has also been used as an antitubercular agent, but its use is limited by its toxicity. -
MAO inhibitor
Olodaterol is a long acting beta-adrenoceptor agonist used as an inhalation for treating patients with chronic obstructive pulmonary disease (COPD), manufactured by Boehringer-Ingelheim. -
MAO-B inhibitor
Lazabemide(Ro 19-6327) is selective, reversible monoamine oxidase B (MAO-B) inhibitor (IC50 values are 0.03 and > 100 μM for MAO-B and MAO-A respectively). -
MAO-B inhibitor
(S)-Rasagiline (TVP1022) is the S-isomer of Rasagiline, which is an anti-Parkinson drug, appears to have the same neuroprotective activity as the R-isomer, but is 1000-fold less active as an MAO-B inhibitor. -
Monoamine oxidase inhibitor
Rasagiline 13C3 mesylate racemic is the deuterium labeled Rasagiline, which is an irreversible inhibitor of monoamine oxidase. -
LSD1/MAO-B inhibitor
Vafidemstat (ORY-2001) is a dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor. -
LOXL2 inhibitor
PAT-1251 is a potent, selective and oral Lysyl Oxidase-Like 2 (LOXL2) inhibitor. -
MAO Inhibitor
Bifemelane hydrochloride is an antidepressant MAO inhibitor. Reverses catalepsy induced by tetrabenazine in mice and increases locomotor activity in MPTP-treated marmosets. -
LSD1/BHC110 & MAO inhibitor
Tranylcypromine hydrochloride is a non-selective MAO-A/B inhibitor. -
HSP90/MAO-A inhibitor
MAO A/HSP90-IN-2 is a dual inhibitor targeting HSP90 and MAO A, exhibiting IC50 values of 0.016 μM and 4.58 μM, respectively. This compound enhances HSP70 expression while concurrently decreasing HER2, phospho-Akt, and IFN-γ induced PD-L1 levels in GL26 cells. It effectively inhibits the growth of both Temozolomide-sensitive and resistant glioblastoma cells, alongside other cancer types such as colon cancer, leukemia, and non-small cell lung cancer. MAO A/HSP90-IN-2 shows promise in addressing tumor immune evasion, making it a valuable tool for cancer research. -
MAO A/HSP90 Inhibitor
MAO A/HSP90-IN-1 is a dual inhibitor targeting MAO A and HSP90, exhibiting IC50 values of 1.77 μM in glioblastoma GL26 cells and 0.019 μM for HSP90α. This compound effectively inhibits MAO A activity, disrupts HSP90 binding, and downregulates HER2 and phospho-Akt expression, leading to reduced growth of glioblastoma cells. Additionally, MAO A/HSP90-IN-1 decreases PD-L1 expression, which may hinder tumor immune escape and suppress T cell activation. This reagent serves as a valuable tool for research on brain tumor-related diseases. -
TMA /TMAO Inhinbitor
3,3-Dimethyl-1-butanol is an orally active inhibitor of trimethylamine (TMA) and trimethylamine N-oxide (TMAO), acting via the suppression of the p65 NF-κB signaling pathway and the TGF-β1/Smad3 pathway. This compound exhibits significant potential in the study of cardiovascular diseases (CVD), making it a valuable reagent for researchers investigating the molecular mechanisms underlying these conditions. -
PTP1B/hMAO-A Inhibitor
Cassiaside B2 is an inhibitor of protein tyrosine phosphatase 1B (PTP1B) and human monoamine oxidase A (hMAO-A). This compound exhibits significant antiallergic properties and functions as a 5-HT2C receptor agonist. It serves as a valuable tool for understanding the modulation of these targets in various biological pathways and contributes to research in neuropharmacology and allergy-related studies. -
MAO-B/Acetylcholinesterase Inhibitor
MAO-B-IN-26 is a selective inhibitor of monoamine oxidase B (MAO-B) and acetylcholinesterase, demonstrating neuroprotective properties against β-amyloid (Aβ) induced cytotoxicity in SH-SY5Y cells. This compound effectively mitigates morphological alterations, reactive oxygen species (ROS) generation, and membrane damage associated with neurodegeneration. Additionally, MAO-B-IN-26 suppresses Aβ-induced autophagy and apoptosis, making it a valuable tool for research focused on therapeutic strategies for Alzheimer's disease. -
Monoamine Oxidase Inhibitor
Harmol is a β-carboline alkaloid functioning as a monoamine oxidase inhibitor and TFEB activator. It has been shown to induce cell mitosis, autophagy, and apoptosis, promoting the degradation of α-synuclein through the autophagy-lysosomal pathway. Harmol exhibits notable anti-tumor, anti-depressant, and anti-aging properties and demonstrates efficacy in improving motor impairments in models of Parkinson's disease. This compound holds significant potential for research in neurodegenerative diseases and cellular autophagy mechanisms. -
MitoNEET Agonist /MAO-B Inhibitor
TT01001 is a selective and orally active mitoNEET agonist and monoamine oxidase B (MAO-B) inhibitor, with an IC50 of 8.84 μM. It functions by preventing mitoNEET-mediated mitochondrial dysfunction, thus attenuating oxidative stress and neuronal apoptosis. TT01001 has demonstrated potential in improving type II diabetes and enhancing mitochondrial function in murine models. This compound is suitable for research focused on type II diabetes and neurological disorders. -
MAO-A/DYRK1A Inhibitor
Norharmine is a Harmine analogue that functions as an inhibitor of monoamine oxidase A (MAO-A) and dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A). It exhibits weak inhibitory activity against MAO-A and demonstrates certain inhibitory effects on DYRK1A, positioning it as a valuable tool for research in neurobiology and cellular signaling pathways. Norharmine is useful in studies focusing on mood disorders and cognitive functions related to these kinase targets. -
MAO-B inhibitor
Quercetin inhibits many enzyme systems including tyrosine protein kinase, phospholipase A2, phosphodiesterases, mitochondrial ATPase, PI 3-kinase and protein kinase C. -
MAO Inhibitor
Safinamide Mesylate is mesylate salt of Safinamide, which selectively and reversibly inhibits MAO-B with IC50 of 0.45 μM. -
MAO B inhibitor
Rasagiline is a selective irreversible inhibitor of MAO-B (monoamine oxidase-B). -
inhibitor of monoamine oxidase-A (MAO-A)
Ro 41-1049 hydrochloride is a reversible and selective inhibitor of monoamine oxidase-A (MAO-A). -
MAO inhibitor
Brofaromine (CGP 11305A) is a monoamine oxidase (MAO) inhibitor with IC50 of 0.2?μM for MAO-A. -
MAO inhibitor
(S)-Rasagiline (TVP1022) mesylate is the S-isomer of rasagiline, which is an anti-Parkinson drug, appears to have the same neuroprotective activity as the R-isomer, but is 1000-fold less active as an MAO-B inhibitor. -
LOXL2 inhibitor
PAT-1251 Hydrochloride is a potent, selective and oral lysyl oxidase-like 2 (LOXL2) inhibitor, with IC50s of 0.71 and 1.17 μM for hLOXL2 and hLOXL3, respectively, and also potently inhibits mouse, rat, and dog LOXL2 (IC50s, 0.10, 0.12, and 0.16 μM, respectively). -
Monoamine Oxidase Inhibitor
Harmol hydrochloride is a potent monoamine oxidase inhibitor that functions as a transcription factor EB (TFEB) activator. It demonstrates significant biological activities, including the induction of cell mitosis, autophagy, and apoptosis. Additionally, Harmol hydrochloride promotes the degradation of α-synuclein by modulating the autophagy-lysosomal pathway, making it relevant in studies of neurodegenerative diseases. Its diverse pharmacological effects also extend to anti-tumor, anti-depressant, and anti-aging activities, and it has shown promise in alleviating motor impairments in models of Parkinson's disease. -
Monoamine Oxidase Inhibitor
4-Hydroxyderricin is a selective inhibitor of Monoamine Oxidase B (MAO-B) with an IC50 of 3.43 μM, making it a valuable tool for studying neurological conditions. In addition to its primary mechanism, it exhibits mild inhibition of dopamine β-hydroxylase activity. This compound has demonstrated a range of biological activities, including antidepressant, anti-allergic, anti-diabetic, antioxidant, and antitumor effects. It has been shown to induce apoptosis and cell cycle arrest in hepatocellular carcinoma cells via modulation of the PI3K/AKT/mTOR pathway, as well as enhance osteoblast differentiation while inhibiting osteoclast formation, positioning it as a promising candidate for research into inflammatory diseases. -
MAO/LSD1 Inhibitor
Tranylcypromine hemisulfate is an irreversible, nonselective inhibitor of monoamine oxidase (MAO) and also acts as a lysine-specific demethylase 1 (LSD1) inhibitor. This compound demonstrates notable antidepressant effects and is utilized in the treatment of depression. Additionally, tranylcypromine hemisulfate has been shown to suppress lesion growth and alleviate generalized hyperalgesia in mouse models of induced endometriosis, making it a valuable tool for research in both psychiatric and pain-related studies.
